Legacy Private Trust Co. Sells 1,861 Shares of Amgen Inc. $AMGN

Legacy Private Trust Co. lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 23.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 6,230 shares of the medical research company’s stock after selling 1,861 shares during the period. Legacy Private Trust Co.’s holdings in Amgen were worth $2,039,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Board of the Pension Protection Fund bought a new position in Amgen in the fourth quarter valued at about $26,000. Evelyn Partners Investment Management LLP bought a new position in shares of Amgen in the second quarter worth about $32,000. Howard Hughes Medical Institute bought a new position in shares of Amgen in the second quarter worth about $32,000. Cloud Capital Management LLC acquired a new stake in shares of Amgen in the 3rd quarter valued at approximately $34,000. Finally, Saranac Partners Ltd acquired a new stake in shares of Amgen in the 3rd quarter valued at approximately $37,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

AMGN stock opened at $347.80 on Friday. The firm has a market cap of $187.49 billion, a price-to-earnings ratio of 24.44, a PEG ratio of 3.45 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The company’s fifty day simple moving average is $360.29 and its 200 day simple moving average is $327.80.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period last year, the business posted $5.31 EPS. The business’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research analyst reports. UBS Group upped their price objective on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Jefferies Financial Group began coverage on shares of Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. Cantor Fitzgerald boosted their target price on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Oppenheimer set a $400.00 price target on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Finally, Citigroup increased their price target on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.